Deazapurine-containing secondary metabolites comprise a broad range of structurally diverse nucleoside analogs found throughout biology including various antibiotics produced by species of Streptomyces bacteria and the hypermodified tRNA bases queuosine and archaeosine. Despite early interest in deazapurines as antibiotic, antiviral, and antineoplastic agents, the biosynthetic route toward deazapurine production has remained largely elusive for more than 40 years. Here we present the first in vitro preparation of the deazapurine nucleoside, preQ 0 , by the successive action of four enzymes. The pathway includes the conversion of the recently identified biosynthetic intermediate, 6-carboxy-5,6,7,8-tetrahydropterin, to a novel intermediate, 7-carboxy-7-deazaguanine (CDG), by an unusual transformation catalyzed by B. subtilis QueE, a member of the radical SAM enzyme superfamily. The carboxylate moiety on CDG is converted subsequently to a nitrile to yield preQ 0 by either B. subtilis QueC or S. rimosus ToyM in an ATP-dependent reaction, in which ammonia serves as the nitrogen source. The results presented here are consistent with early radiotracer studies on deazapurine biosynthesis and provide a unified pathway for the production of deazapurines in nature.Compounds containing pyrrolopyrimidine functional groups, collectively referred to as 7-deazapurines, are a structurally diverse class of nucleoside analogs with demonstrated antibiotic, antineoplastic, and antiviral activities. Deazapurine containing compounds include the nucleoside antibiotics toyocamycin, sangivamycin, tubercidin, and cadeguomycin ( Figure 1), which are produced by various species of Streptomyces (1,2). In addition, the hypermodified base, queuosine (Figure 1), which is located in the wobble position of 5′-GUN-3′ anticodons in tRNA in a number of organisms (except yeast (3)) bearing tyrosine, histidine, asparagine and aspartate contains a deazapurine moiety (4). The occurrence of queuosine in tRNA is